Spondyloarthritis & psoriatic arthritis
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
Authors' conclusion
Guselkumab demonstrates better skin efficacy than most other targeted PsA therapies, including upadacitinib. For vdH-S, both guselkumab doses are comparable to most treatments, with both doses ranking higher than most, including upadacitinib and risankizumab. Both guselkumab doses demonstrate comparable ACR responses to most other agents, including upadacitinib and risankizumab, and rank favourably in the network for SAEs.
Study context
- Population
- RCTs of targeted therapies for PsA (systematic literature review up to February 2021; hand-search of newer agents up to July 2021)
- Comparison
- Guselkumab 100 mg Q8W and Q4W vs other targeted therapies for PsA, including risankizumab and upadacitinib
Methodological detailsBayesian network meta-analysis (NMA), update of previous NMA
- Bayesian NMA
- Update of previous NMA
Pooled result
As reported in the abstract
- ACR 20: guselkumab Q8W and Q4W comparable (overlapping CrIs) to most other agents, incl. risankizumab, upadacitinib, subcutaneous TNFi and most IL-17A inhibitors
- Psoriasis Area and Severity Index (PASI) 90: guselkumab Q8W and Q4W better than multiple agents, incl. subcutaneous TNF and Janus kinase (JAK) inhibitors
- Van der Heijde-Sharp (vdH-S): guselkumab Q8W similar to risankizumab, Q4W better; both doses comparable to most other agents
- CrI
Safety
Serious adverse events
- Most agents had comparable SAEs
Original publication
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford). Published 14 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →